louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06660537: Effects of Balloon-blowing Exercises in 90/90 Bridge Position With a Ball on Pulmonary Function Among Asthmatic Patients
Official title: Effects of Balloon-blowing Exercises in 90/90 Bridge Position With a Ball on Pulmonary Function Among Asthmatic Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Asthma
Keywords: Dyspnea, asthma, spirometry, quality of life, oxygen saturation
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-10-28
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a randomized controlled trial having two groups. One group will receive (interventional group) balloon-blowing exercises in 90/90 bridge position with a ball and the other group (control group) will receive buteyko breathing exercises.
Primary purpose: TREATMENT

Brief summary: In asthma, the airways in the respiratory system can experience inflammation and constriction, causing increased difficulty in expelling air during exhalation. This results in disruptions to respiratory parameters, exercise intolerance, and a diminished overall quality of life.Engaging in balloon-blowing exercises while in a 90/90 bridge position with the use of a ball will lead to enhanced pulmonary function and quality of life in individuals with asthma.

Detailed description: Asthma attacks and labored breathing can cause strain and weakness in the diaphragm, the main muscle supporting breathing, as well as the muscles of core.

The study objective is to determine the effects of balloon-blowing exercises in 90/90 bridge posotion with a ball on pulmonary function and quality of life among asthmatic patients.

Eligibility criteria: Inclusion Criteria:

* Adults: aged (18-59 years)
* Gender: Both male and females
* Grade1- Grade 4 on Modified MRC dyspnea scale
* Asthma severity ( level 1 mild intermediate, levell 2 mild persistent)

Exclusion criteria:

* Level 3 and above asthmatics or status asthmatics.
* Any congenital deformities of chest wall/ Heart/ Lungs.
* Demonstrated neuromuscular or neurological deficit/ chest wall deformity.
* Cardiopulmonary diseases including coronary artery disease(CAD), Pulmonary HTN, ------Aortic Stenosis, regurgitation, etc.
* Any Autoimmune disease with manifestations of Chest wall/ heart/ Lungs.
* Any recent cardiothoracic or abdominal surgery or sternotomy.
* Recent history of the blunt chest wall or abdominal trauma.
* Unstable hemodynamic parameters (arterial pressure \>140mmhg systolic and \>90mmhg for diastolic).
* Pregnancy

Primary outcomes:
measure: pulmonary function test
timeFrame: 4 weeks
measure: Dyspnea
timeFrame: 4 weeks
measure: Quality of life of patient
timeFrame: 4 Weeks
measure: Oxygen Saturation
timeFrame: 4 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT00373737: Microarray Analysis of Gene Expression in Liver Tumors
Official title: Microarray Analysis of Gene Expression in Liver Tumors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2006-09-08
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with liver tumors undergoing partial liver resection, open liver biopsy, and patients undergoing liver transplantation with or without liver tumors at Stanford University

Brief summary: This study aims to study the gene expression profiles of liver tumors to help us understand their biology, and to find new tumor and treatment markers for liver cancer.

Detailed description: The purpose of this research is to study of the biologic features of liver tissue (by studying their gene expression profiles), so that we can increase our understanding of the processes involved in liver cancer development and growth. This may allow us to identify more effective ways of diagnosing, treating, and predicting the outcome of patients with liver cancer.

Eligibility criteria: Inclusion Criteria:Inclusion Criteria:

* Patients with liver tumors undergoing partial liver resection, open liver biopsy, and patients undergoing liver transplantation with or without liver tumors at Stanford University
* Patients older than 18

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Samuel So
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04788537: Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders
Official title: Services to Enhance Social Functioning in Adults With Autism Spectrum Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Autism
Autism Spectrum Disorder
Autistic Disorder
Asperger Syndrome
Pervasive Developmental Disorder
Keywords: Autism
Autism Spectrum Disorder
Cognitive Behavioral Therapy
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2021-03-09
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants randomly assigned to either the intervention group (50%) or nonintervention group (50%).
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test a novel, three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder.

The treatment, named TUNE In (Training to Understand and Navigate Emotions and Interactions), includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.

The Investigators will test the efficacy of TUNE In to improve social functioning in adults with autism spectrum disorder (ASD), using a randomized controlled trial using the SRS-2 as the primary outcome measure.


Eligibility criteria: Inclusion Criteria:

* diagnosis of autism spectrum disorder

Exclusion Criteria:

* intellectual disability
* severe mood or psychotic symptoms experienced in the past 4 weeks
* severe self-injurious or aggressive behavior
* severe extrapyramidal motor or sedating side effects of medications
* concomitant participation in another social skills treatment program.

Primary outcomes:
measure: Reduction in Social Responsiveness Scale, Second Edition (SRS-2) - Adult (Relative/Other Report)
timeFrame: Baseline and Post-Treatment (~1 year after baseline)
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Perelman School of Medicine
state: Pennsylvania
Study officials:
References:
Clinical trial NCT03956537: PMCF Neo Pedicle Screw and Cage Systems
Official title: Fusion With the Neo Pedicle Screw and Cage Systems: A Post Market Clinical Follow-up Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Degenerative Disc Disease
Spondylolisthesis
Spinal Stenosis
Spinal Tumor
Trauma
Pseudoarthrosis of Spine
Lead sponsor: Neo Medical SA
Sponsor class: INDUSTRY
Collaborators: name: ConfinisCPM
First posted: 2019-05-20
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: In total, approximately 150 patients will be recruited and enrolled to ensure that at least 132 patients are evaluable at 12 and 24 months. Patients are recruited consecutively, retrospectively as well as prospectively. The potential patients to be recruited have either already been implanted or are planned to be implanted with the Neo Pedicle Screw System (Arm 1) or Neo Cage System and Neo Pedicle Screw System (Arm 2).

Brief summary: The objectives of this clinical observational study is to evaluate the safety and efficacy (performance) of the Neo Pedicle Screw System™ and the Neo Cage System™ interbody fusion device. To demonstrate non-inferiority of safety and function to an historical control from the published medical literature on competitive devices.


Eligibility criteria: Inclusion criteria:

* Patient has undergone or is intended to undergo surgery with the Neo Pedicle Screw System™, standalone or in combination with the Neo Cage System™, for any of the approved indications as defined in the respective labelling
* Patient has participated in or is willing to participate in the routine postoperative follow-up program
* Patient is willing to provide written informed consent

Exclusion criteria:

* Patient is under the age of 18 or skeletally immature
* Patient had or has a contraindication to surgery or to any of the implant systems used in the study, as defined in the respective labelling

Primary outcomes:
measure: Change in patient´s function from baseline to 12 months
timeFrame: 12 months
measure: The rate of cage migration in cage-plus-screw systems.
timeFrame: 12 months and 24 months post operatively
measure: The rate of pedicle screw loosening in screw only and cage-plus-screw systems.
timeFrame: 12 months and 24 months post operatively
Secondary outcomes:
Other outcomes:
Locations:
city: Sande
country: Germany
facility: Dep. of Neurosurgery, Nordwest Krankenhaus Sanderbusch
city: Valladolid
country: Spain
facility: Spine Center, University Hospital Valladolid
Study officials:
affiliation: Spine Center, University Hospital Valladolid, Valladolid, Spain
name: David C Noriega, PhD, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dep. of Neurosurgery, Nordwest Krankenhaus Sanderbusch, Sande, Germany
name: Yasser Abdalla, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01902537: An Observational Study to Evaluate the Quality of Life in Korean Female Participants With Chronic Constipation
Official title: Health Related Quality of Life in Female Patients With Chronic Constipation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Constipation
Keywords: Constipation
Prucalopride
Lead sponsor: Janssen Korea, Ltd., Korea
Sponsor class: INDUSTRY
First posted: 2013-07-18
Enrollment: 150
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Korean female participants with chronic constipation, having received treatment previously for constipation. Participants who have visited Constipation Clinic of AMC or Department of Gastrointestinal for constipation therapy will be selected.

Brief summary: The purpose of this observational study is to investigate health related quality of life (QoL) in Korean female participants with chronic constipation (long term decreased number of or difficulty making bowel movements) having received treatment previously.

Detailed description: This is a cross-sectional (studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at 1 particular time) observational study (a scientific study to make a clear and easy understanding of the cause and effect relationship) to investigate the health related QoL in Korean female participants with chronic constipation having received treatment previously by using EQ-5D (EuroQol 5 Dimension), SF-36 (Short Form Health Survey) and PAC-QoL (Patient Assessment of Constipation) questionnaires. The duration of study will be 6 months. Participant's safety will be monitored throughout the study.

Eligibility criteria: Inclusion Criteria:

-Korean female participants with chronic constipation having received treatment previously

Exclusion Criteria:

* Male participants
* Participants with psychological disease (disorders of the mind, thoughts, and behavior)

Primary outcomes:
measure: EQ-5D-3L (EuroQol 5 Dimension 3 Level) Quality of life (QoL) Score at Baseline
timeFrame: Baseline
measure: EQ-5D-3L (EuroQol 5 Dimension) Quality of life (QoL) Score at Week 1
timeFrame: Week 1
measure: EQ-5D-5L (EuroQol 5 Dimension 5 Level) Quality of life (QoL) Score at Baseline
timeFrame: Baseline
measure: EQ-5D-5L (EuroQol 5 Dimension 5 Level) Quality of life (QoL) Score at Week 1
timeFrame: Week 1
measure: Short Form 36 (SF-36) Quality of life (QoL) Score
timeFrame: Baseline
measure: Participant Assessment of Constipation Quality of Life (PAC-QoL) Scale Score
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
Study officials:
affiliation: Janssen Korea, Ltd., Korea
name: Janssen Korea, Ltd., Korea Clinical Trial
role: STUDY_DIRECTOR
References:
Clinical trial NCT04642937: Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Official title: Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Glioblastoma
Lead sponsor: OX2 Therapeutics
Sponsor class: INDUSTRY
First posted: 2020-11-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.


Eligibility criteria: Inclusion Criteria:

* Aged 18 years and older.
* Confirmed diagnosis of GBM.
* Radiographically or histologically proven progression or recurrence of disease at any time after standard of care therapy (radiation, temozolomide, with or without a tumor treatment field device).
* Tumor debulking or biopsies may be performed to clinical trial enrollment if indicated and feasible.

Exclusion Criteria:

* Bevacizumab or targeted therapy within 45 days of enrollment.
* Intercurrent immune system disorder such as hypoimmunity (marrow failure, HIV) or hyperimmunity (autoimmune disease).
* Unable to complete a standard upfront course of chemoradiotherapy due to disease progression or intolerance of therapy.
* History of Gliadel water, GammaTile or other implanted therapeutic agent.
* Concurrent use of tumor treatment field devices (e.g. Optune).

Primary outcomes:
measure: Maximum tolerated dose (MTD) of hP1A8 when administered with imiquimod and GBM6-AD
timeFrame: 12 months
Secondary outcomes:
measure: Incidence of serious adverse events (SAEs)
timeFrame: 12 months
measure: Time to progression (TTP)
timeFrame: 24 months
measure: Progression free survival (PFS)
timeFrame: 24 months
measure: Overall survival (OS)
timeFrame: 24 months
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
References:
Clinical trial NCT02036437: Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor
Official title: Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Medical Induction of Labor Affecting Fetus
Keywords: Induction of Labor
Misoprostol
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2014-01-15
Enrollment: 200
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To test the safety and efficacy of titrated oral misoprostol compared to vaginal dinoprostone for labor induction.

Detailed description: * There are many indications for induction of labor in the obstetric practice, of which prolonged gestational age stands as the most common indication. It is well recognized that with an unripe cervix, induction may be difficult and often unsuccessful. The use of an agent to ripen the cervix prior to induction is acceptable in the modern practice.
* Misoprostol, a prostaglandin E1 analogue, is the most interesting alternative to Dinoprostone because of its effectiveness, low cost, and temperature stability. It ripens the cervix by inducing regular uterine contractions. However, it is associated with several adverse effects especially uterine hyperstimulation, which is painful and may result in fetal compromise.
* Testing the efficacy and safety of titrated oral misoprostol versus vaginal dinoprostone may develop a new safe and effective method for labor induction.

Eligibility criteria: Inclusion Criteria:

* Single vertex presentation.
* Gestational age \> 37 weeks calculated from last menstrual period or U/S scanning.
* Bishop score \<8 .
* Not in labor.
* Reassuring fetal heart rate (CTG for 20 min on the day of induction).
* Valid indication for Induction of labor.

Exclusion Criteria:

* Gestational age \<37 weeks.
* Patients with rupture of membranes.
* Previous uterine scar.
* Fetal malpresentation.
* Multiple pregnancy.
* Significant antepartum hemorrhage
* Uncontrolled DM.
* Severe Pre-eclampsia or Eclampsia
* If there are contraindications to receive the drugs, e.g. allergy, history of severe asthma,.....etc.

Primary outcomes:
measure: Induction delivery interval i.e. Time from start of medication till delivery
timeFrame: 24 hours
Secondary outcomes:
measure: Patients delivered vaginally within the first 24 hours
timeFrame: 24 hours
measure: Time from start of labor augmentation by either misoprostol or Syntocinon (oxytocin) to active phase of labor
timeFrame: 12 hours
measure: Duration of 1st,2nd and 3rd stages of labor
timeFrame: 24 hours
measure: Maternal complications
timeFrame: 24 hours
measure: Mode of delivery
timeFrame: 24 hours
measure: Neonatal outcome
timeFrame: 24 hours
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: New Maternity Hospital - Ain Shams university
Study officials:
affiliation: Ain Shams University
name: Amr H Yehia, MD, MRCOG
role: STUDY_DIRECTOR
References:
Clinical trial NCT06572137: Prevalence of Parental Burnout Among Mothers of Children With Cerebral Palsy
Official title: Prevalence of Parental Burnout Among Mothers of Children With Cerebral Palsy: Cross Sectional Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Parents
Burnout
Children, Only
Cerebral Palsy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-08-26
Enrollment: 380
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The estimated prevalence of burnout among mothers of children with cerebral palsy is 65% with expected prevalence 56%

Brief summary: This study will be done to determine the prevalence of Parental Burnout among mothers of children with cerebral palsy.

Determine the relation between Parental Burnout syndrome and the motor function levels of children with cerebral palsy.

Detailed description: Cerebral palsy is a significant physical disability in children, affecting 2-5 children per 1,000 live births globally. The prevalence varies between countries and is higher in low- and middle-income countries. Studies suggest a relationship between children's motor impairment and parental stress, which can lead to illness, negative family dynamics, and neglect. Parenting stress and pressure have increased, leading to exhaustion and burnout among parents. This study aims to investigate the prevalence of Parental Bowel Syndrome among mothers of children with CP and its relation to motor function levels.

Eligibility criteria: Inclusion Criteria:

* Mothers of children with CP of any age.
* Children diagnosed with CP.
* The age of children will range from 3-18 years old.

Exclusion Criteria:

* Mothers who refuse to participate in the study.
* Mothers of more than one disabled child.

Primary outcomes:
measure: assessment of 4 dimensions of burnout
timeFrame: at baseline
Secondary outcomes:
measure: assessment of gross motor function
timeFrame: at baseline
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: out-patient clinic, faculty of physical therapy, Cairo university
Study officials:
References:
Clinical trial NCT04904237: Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
Official title: Azacytidine-venetoclax Combination as Leukemia Debulking Treatment Followed by Reduced Toxicity Conditioning Regimen (Melphalan Busulfan and Fludarabine, MBF) as Salvage Therapy for Refractory Acute Myeloid Leukemia (AML).
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Refractory Acute Myeloid Leukemia
Keywords: refractory
acute myeloid leukemia
hematopoietic stem cell transplantation
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2021-05-27
Enrollment: 23
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen consisting of Fludarabine + Busulfan + Melphalan as salvage treatment in patients with refractory AML .

Detailed description: In refractory AML, allogeneic hematopoietic stem cell transplantation (allo-HCST) is considered as the only curative regimen. In this phase II clinical trial, we plan to evaluate the efficacy and feasibility of new sequential transplantation protocol. All patients receive azacytidine and venetoclax as leukemia debulking treatment which is followed by reduced intensity conditioning regimen consisting of Fludarabine (150mg/m2) + Busulfan (6.4mg/kg) + Melphalan (70mg/m2). The graft-versus host disease (GVHD) prophylaxis regimen is based on reduced dose of post-transplantation cyclophosphamide (PT-CY) 40mg/kg day+3\~+4, tacrolimus and low-dose anti-thymoglobulin (ATG, 2.5mg/kg) in case of HLA-matched unrelated donor or halo-donor transplantation.

Eligibility criteria: Inclusion Criteria:

* refractory AML (no remission after 2 induction therapy, relapsed AML within 6 months of first complete remission (CR), relapse AML no CR after reinduction therapy), multiple relapse and refractory relapse AML
* patients with HLA matched related or unrelated donor (9\~10/10) or haplo-identical related donor

Exclusion Criteria:

* Patients with poor liver function (enzyme \>2N or bilirubin \>2N)
* poor renal function (Scr \>1.5N)
* poor cardiac function （EF\<45%）
* inform consent not provided

Primary outcomes:
measure: relapse-free survival
timeFrame: 12 months
Secondary outcomes:
measure: overall survival
timeFrame: 12 months
measure: non-relapse mortality
timeFrame: 12 months
measure: relapse
timeFrame: 12 months
measure: GVHD and relapse free survival (GRFS)
timeFrame: 12 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Blood & Marrow Transplantation Center, RuiJin Hospital
city: Shanghai
country: China
facility: Department of Hematology, Shanghai No6 Hospital
city: Shanghai
country: China
facility: Shanghai ZhaXin Hospital
Study officials:
affiliation: Shanghai Rui Jin Hospital
name: Jiong HU
role: PRINCIPAL_INVESTIGATOR
References: